Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Lainie P. Martin's publication output changed over time?
ScholarIQpublication output · 2008–2025
Output grew0% over the shown period — from 1 works in 2008 to 1 in 2025.
1
1
1
2
2
1
1
1
1
200820122014201620172021202220232025
What are the most-cited papers on Lainie P. Martin?
ScholarIQmost cited works
Platinum Resistance: The Role of DNA Repair Pathways
Lainie P. Martin, Thomas C. Hamilton, Russell J. Schilder
Clinical Cancer Research. 2008759 Citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Joyce F. Liu, Haider Mahdi, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac‐Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh
Journal of the National Comprehensive Cancer Network. 2021727 CitationsOPEN ACCESS
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Yolanda García García, Susana Banerjee, Domenica Lorusso, Jung‐Yun Lee, John W. Moroney, Nicoletta Colombo, A. Roszak, Jacqueline M. Tromp, Tashanna Myers, Jeong‐Won Lee, Mario Beiner, Casey Cosgrove, David Cibula, Lainie P. Martin, Renaud Sabatier, Joseph Buscema, Purificación Estévez-García, Lan Coffman, Shibani Nicum, Linda Duska, Sandro Pignata, Fernando Gálvez, Yuemei Wang, Michael Method, Anna Berkenblit, Diana Bello Roufai, Toon Van Gorp
New England Journal of Medicine. 2023447 CitationsOPEN ACCESS
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Gary S. Leiserowitz, Joyce F. Liu, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac‐Lima, Steven W. Remmenga, John O. Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsíros, Mary A. Dwyer, Lisa E. Hang
Journal of the National Comprehensive Cancer Network. 2022404 CitationsOPEN ACCESS
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O’Malley, Matthew Boente, Helen Michael, Bradley J. Monk
New England Journal of Medicine. 2016369 CitationsOPEN ACCESS
Related on ScholarIQ
Argosy University
Institution
Platinum Resistance: The Role of DNA Repair Pathways
Paper
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Paper
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Paper
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Paper
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Paper